NX-5948
Showing 26 - 36 of 36
Prostate Cancer Trial in United States (NX-1207 2.5 mg, NX-1207 15 mg)
Completed
- Prostate Cancer
- NX-1207 2.5 mg
- NX-1207 15 mg
-
Tucson, Arizona
- +22 more
Mar 9, 2017
Benign Prostatic Hyperplasia (BPH) Trial in United States (NX-1207, Placebo)
Completed
- Benign Prostatic Hyperplasia (BPH)
- NX-1207
- Placebo
-
Laguna Hills, California
- +34 more
Mar 9, 2017
Breast Tumors Trial in Urumchi (EndostarTM Injection, Gemcitabine, Navelbine)
Unknown status
- Breast Neoplasms
- EndostarTM Injection
- +4 more
-
Urumchi, Xinjiang, ChinaThird Affiliated Hospital of Xinjiang Medical University
Jul 12, 2017
Opioid Dependence Trial in Birmingham (Buprenorphine and naloxone)
Withdrawn
- Opioid Dependence
- Buprenorphine and naloxone
-
Birmingham, Alabama(unnamed)
May 2, 2017
Opiate-related Disorders Trial in United States (Buprenorphine/naloxone, Methadone)
Completed
- Opiate-related Disorders
-
Los Angeles, California
- +8 more
Nov 9, 2016
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate Trial in United States (2.5 mg NX-1207, 0.125 mg NX-1207, finasteride)
Completed
- Benign Prostatic Hyperplasia (BPH)
- Enlarged Prostate
- 2.5 mg NX-1207
- +2 more
-
Huntsville, Alabama
- +29 more
Jun 12, 2012
Carcinoma, Invasive Ductal, Breast Trial in Beijing (Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine,
Unknown status
- Carcinoma, Invasive Ductal, Breast
- Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine
- Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
-
Beijing, ChinaCancer Institute and Hospital, Chinese Academy of Medical Scienc
May 3, 2011
